11β-hydroxysteroid dehydrogenase activity in proteinuric patients and the effect of angiotensin-II receptor blockade

European Journal of Clinical Investigation

Volumn 32, Issue 7, 2002, Pages 513-518

  Kerstens, M N ^a   Buter, H ^b   Navis, G J ^b   Dullaart, R P F ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

11 HSD; Losartan; Proteinuria

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ANGIOTENSIN 2 RECEPTOR; CORTISONE; HYDROCORTISONE; LOSARTAN; TETRAHYDROCORTISOL; TETRAHYDROCORTISONE; ANGIOTENSIN RECEPTOR; CORTODOXONE; DRUG DERIVATIVE; HYDROXYSTEROID DEHYDROGENASE; TETRAHYDRO 11 DEOXYCORTISOL; TETRAHYDRO-11-DEOXYCORTISOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; FEMALE; HORMONE METABOLISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; KIDNEY; MALE; MEAN ARTERIAL PRESSURE; METABOLITE; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR BLOCKING; URINARY EXCRETION; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; RANDOMIZED CONTROLLED TRIAL; URINE;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ADULT; CASE-CONTROL STUDIES; CORTISONE; CORTODOXONE; FEMALE; HUMANS; HYDROCORTISONE; HYDROXYSTEROID DEHYDROGENASES; KIDNEY; LOSARTAN; MALE; PROTEINURIA; RECEPTORS, ANGIOTENSIN; TETRAHYDROCORTISOL; TETRAHYDROCORTISONE;

EID: 0036882130     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.01013.x     Document Type: Article

References (36)

1. Stewart PM, Krozowski ZS. 11β-hydroxysteroid dehydrogenase. Vitam Horm 1999;57:249-324.
2. Tannin GM, Agarwal AK, Monder C, New MI, White PC. The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 1991;266:16653-8.
3. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM. Immunohistochemical localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 1998;83:1325-35.
4. Stewart PM, Murry BA, Mason JI. Human kidney 11β-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab 1994;79:480-4.
5. Lakshmi V, Monder C. Purification and characterization of the corticosteroid 11β-dehydrogenase component of the rat liver 11β-hydroxysteroid dehydrogenase complex. Endocrinology 1988;123:2390-8.
6. Agarwal AK, Tusie-Luna MT, Monder C, White PC. Expression of 11β-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol Endocrinol 1990;4:1827-32.
7. Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CR. Mineralocorticoid excess and inhibition of 11β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) 1992;37:483-92.
8. Jamieson PM, Chapman KE, Edwards CR, Seckl JR. 11β-hydroxysteroid dehydrogenase is an exclusive 11β - reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 1995;136:4754-61.
9. Rusvai E, Náray-Fejes-Tóth A. A new isoform of 11β-hydroxysteroid dehydrogenase in aldosterone target cells. J Biol Chem 1993;268:10717-20.
10. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994;105:R11-R17.
11. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979;49:757-64.
12. Palermo M, Shackleton CH, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 1996;45:605-11.
13. Best R, Walker BR. Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11β-hydroxysteroid dehydrogenase in vivo. Clin Endocrinol (Oxf) 1997;47:231-6.
14. Lin CL, Wu TJ. Machacek DA, Jiang NS, Kao PC. Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1997;82:151-5.
15. Kasuya Y, Shibasaki H, Furuta T. The use of deuterium-labeled cortisol for in vivo evaluation of renal 11β-HSD activity in man: urinary excretion of cortisol, cortisone and their A-ring reduced metabolites. Steroids 2000;65:89-97.
16. Vogt B, Dick B, N'Gankam V, Frey FJ, Frey BM. Reduced 11β-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome. J Clin Endocrinol Metab 1999;84:811-4.
17. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996;49:1787-90.
18. Nielsen S, Dollerup J, Nielsen B, Jensen HA, Mogensen CE. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997;12 (Suppl. 2):19-23.
19. Lozano JV, Llisterri JL, Aznar J, Redon J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001;16 (Suppl. 1):85-9.
20. Buter H, Navis G, Dullaart RP, de Zeeuw D, de Jong PE. Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 2001;16:771-5.
21. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
22. Riddle MC, McDaniel PA. Renal 11β-hydroxysteroid dehydrogenase activity is enhanced by ramipril and captopril. J Clin Endocrinol Metab 1994;78:830-4.
23. Ricketts ML, Stewart PM. Regulation of 11β-hydroxysteroid dehydrogenase type 2 by diuretics and the renin-angiotensin-aldosterone axis. Clin Sci (Colch) 1999;96:669-75.
24. Hermans JJR, Fischer MA, Schiffers PM, Struijker-Boudier HA. Effect of angiotensin II on rat renal cortical 11β-hydroxysteroid dehydrogenase. Endocrine 2000;3:393-9.
25. Dullaart RPF, Ubels FL, Hoogenberg K, Smit AJ, Pratt JJ, Muntinga JHJ et al. Alterations in cortisol metabolism in insulin-dependent diabetes mellitus: relationship with metabolic control and estimated blood Volume and effect of angiotensin-converting enzyme inhibition. J Clin Endocrinol Metab 1995;80:3002-8.
26. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
27. Pratt JJ. Steroid immunoassay in clinical chemistry. Clin Chem 1978;24:1869-90.
28. Kerstens MN, Riemens SC, Sluiter WJ, Pratt JJ, Wolthers BG, Dullaart RPF. Lack of relationship between 11β-hydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24 h of insulin infusion in healthy subjects and type 2 diabetic patients. Clin Endocrinol (Oxf) 2000;52:403-11.
29. Wolthers BG, de Vries IJ, Volmer M, Nagel GT. Detection of 3β-hydroxysteroid dehydrogenase deficiency in a newborn by means of urinary steroid analysis. Clin Chim Acta 1987;169:109-16.
30. Zumoff B, Fukushima DK, Hellman L. Intercomparison of four methods for measuring cortisol production. J Clin Endocrinol Metab 1974;38:169-75.
31. Andrew R, Phillips DIW, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998;83:1806-9.
32. Weaver JU, Taylor NF, Monson JP, Wood PJ, Kelly WF. Sexual dimorphism in 11β hydroxysteroid dehydrogenase activity and its relation to fat distribution and insulin sensitivity; a study in hypopituitary subjects. Clin Endocrinol (Oxf) 1998;49:13-20.
33. Stewart PM, Boulton A, Kumar S, Clark PMS, Shackleton CHL. Cortisol metabolism in human obesity: impaired cortisone → cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999;84:1022-7.
34. Escher G, Meyer KV, Vishwanath BS, Frey BM, Frey FJ. Furosemide inhibits 11β-hydroxysteroid dehydrogenase in vitro and in vivo. Endocrinology 1995;136:1759-65.
35. Walker BR, Stewart PM, Shackleton CHL, Padfield PL, Edwards CRW. Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol (Oxf) 1993;39:221-7.
36. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R. Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in subjects with untreated essential hypertension.Hypertension 1995;25:67-70.